Trial Profile
A clinical study comparing pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Immunological disorders
- Focus Adverse reactions
- Sponsors Bioeq
- 25 Apr 2023 Results presented in the Formycon Media Release.
- 01 Feb 2023 Status changed from recruiting to active, no longer recruiting, according to a Formycon media release.
- 01 Feb 2023 According to a Formycon media release, the recruitment of study subjects from phase I pharmacokinetics study was successfully completed in October 2022.